CIK 0001061983
- Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 943291317
- Phone
- +1 650-624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,320,469
- in 18 filings, $12.5M under 10b5-1 plans
Net −$13,320,469. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Blum Robert I −$9.7M President & CEO sold 34% of stake
- Malik Fady Ibraham −$1.3M EVP Research & Development sold 12% of stake
- Hessekiel Jeffrey −$795K Chief Legal & Admin Officer sold 14% of stake
- Callos Andrew −$702K EVP, Chief Commercial Officer sold 15% of stake
- PARSHALL B LYNNE −$631K Director sold 63% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-08 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,500 | $38.07 | $95K | 163,164 |
| 2023-05-31 | Blum Robert I President & CEO | Exercise or conversion 10b5-1 | +12,500 | $9.65 | $121K | 453,558 |
| 2023-05-31 | Blum Robert I President & CEO | Sale 10b5-1 | −12,500 | $37.67 | $471K | 441,058 |
| 2023-05-31 | Blum Robert I President & CEO | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −12,500 | 58,191 | ||
| 2023-05-16 | Blum Robert I President & CEO | Exercise or conversion 10b5-1 | +12,500 | $9.65 | $121K | 453,558 |
| 2023-05-16 | Blum Robert I President & CEO | Sale 10b5-1 | −12,500 | $37.41 | $468K | 441,058 |
| 2023-05-16 | Blum Robert I President & CEO | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −12,500 | 70,691 | ||
| 2023-05-15 | HENDERSON JOHN T Director | Exercise or conversion 10b5-1 | +4,166 | $6.78 | $28K | 29,586 |
| 2023-05-15 | HENDERSON JOHN T Director | Sale 10b5-1 | −4,166 | $37.77 | $157K | 25,420 |
| 2023-05-15 | HENDERSON JOHN T Director | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −4,166 | 0 | ||
| 2023-05-11 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −1,787 | $39.50 | $71K | 165,396 |
| 2023-05-10 | SMITH SANDFORD D Director | Grant or award | +5,000 | 17,831 | ||
| 2023-05-10 | SMITH SANDFORD D Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2023-05-10 | WIERENGA WENDALL Director | Grant or award | +5,000 | 17,831 | ||
| 2023-05-10 | WIERENGA WENDALL Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2023-05-10 | Wysenski Nancy Director | Grant or award | +5,000 | 16,671 | ||
| 2023-05-10 | Wysenski Nancy Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2023-05-10 | PARSHALL B LYNNE Director | Grant or award | +5,000 | 15,000 | ||
| 2023-05-10 | PARSHALL B LYNNE Director | Grant or award · Non-Qualified Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2023-05-10 | Kaye Edward M. MD Director | Grant or award | +5,000 | 18,347 |
Page 41 of 45 · 885 trades